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Abstract 
Background 
The rearrangements in the 22q11.2 chromosomal region, responsible for the 22q11.2 deletion 
and microduplication syndromes, are frequently associated with congenital heart disease 
(CHD). The present work aimed to identify the genetic basis of CHD in 87 patients from the 
São Miguel Island, Azores, through the detection of copy number variants (CNVs) in the 
22q11.2 region. These structural variants were searched using multiplex ligation-dependent 
probe amplification (MLPA). In patients with CNVs, we additionally performed fluorescent 
in situ hybridization (FISH) for the assessment of the exact number of 22q11.2 copies among 
each chromosome, and array comparative genomic hybridization (array-CGH) for the 
determination of the exact length of CNVs. 
Results 
We found that four patients (4.6%; A to D) carried CNVs. Patients A and D, both affected 
with a ventricular septal defect, carried a de novo 2.5 Mb deletion of the 22q11.2 region, 
which was probably originated by inter-chromosomal (inter-chromatid) non-allelic 
homologous recombination (NAHR) events in the regions containing low-copy repeats 
(LCRs). Patient C, with an atrial septal defect, carried a de novo 2.5 Mb duplication of 
22q11.2 region, which could have been probably generated during gametogenesis by NAHR 
or by unequal crossing-over; additionally, this patient presented a benign 288 Kb duplication, 
which included the TOP3B gene inherited from her healthy mother. Finally, patient B showed 
a 3 Mb triplication associated with dysmorphic facial features, cognitive deficit and heart 
defects, a clinical feature not reported in the only case described so far in the literature. The 
evaluation of patient B’s parents revealed a 2.5 Mb duplication in her father, suggesting a 
paternal inheritance with an extra copy. 
Conclusions 
This report allowed the identification of rare deletion and microduplication syndromes in 
Azorean CHD patients. Moreover, we report the second patient with a 22q11.2 triplication, 
and we suggest that patients with triplications of chromosome 22q11.2, although they share 
some characteristic features with the deletion and microduplication syndromes, present a 
more severe phenotype probably due to the major dosage of implicated genes. 
Keywords 
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Background 
Congenital heart disease (CHD) affects about 12 in 1000 live births and includes structural 
heart defects which impair the cardiac function [1]. The pathogenesis of these defects is 
largely unknown, but it is widely reported that genetic factors play an important role in the 
complex aetiology of CHD [2]. Although much of these diseases are thought to have a 
complex genetic and/or environmental aetiology, an increasing number of families with 
monogenic CHD have been reported and disease-causing genes are being identified [3]. 
Additionally, recurrent copy number variants (CNVs) have been also found in a significant 
proportion of patients with CHD [2]. These structural variants are strongly associated with 
genetic syndromes [1]. The most common example is the 22q11.2 deletion syndrome, which 
is estimated to affect approximately 1 in 4000 live births [4] and results most commonly from 
a 3 Mb deletion in the 22q11.2 region [4-7]. This region contains approximately 40 genes [8], 
being the TBX1 and COMT the most relevant [9]. Genomic rearrangements in the 22q11.2 
region are due to the presence of several copies of low-copy repeat sequences (LCR22) that 
mediate inter-chromosomal (inter-chromatid) non-allelic homologous recombination 
(NAHR) [4,7,10]. 
The 22q11 deletion phenotype is highly variable and includes the following characteristics: 
cardiovascular anomalies; palatal abnormalities; nasal voice; immune deficiency related with 
hypoplasia of the thymus; endocrine dysfunctions, such as hypocalcaemia; a varying degree 
of cognitive defects and intellectual disability; velopharyngeal insufficiency; and a 
characteristic craniofacial dysmorphism [5,6,11,12]. 
Microduplications of 22q11.2 have recently been characterized as a new genomic duplication 
syndrome [8,13], by sharing some clinical features with the 22q11.2 deletion syndrome. They 
show an extremely variable phenotype, ranging from normal or mild learning disability to 
multiple congenital defects, such as: heart defects, velopharyngeal insufficiency with and 
without cleft palate, growth delay, mild dysmorphic features, and behavioural abnormalities 
[5,8,13-15]. The large majority of affected individuals have 3 Mb duplications of the 
typically deleted region including the TBX1 gene [8]. Regarding other CNVs, Yobb and 
colleagues [14] reported one patient with a triplication of the 3 Mb 22q11.2 deletion 
syndrome region, and suggested that this structural variant only causes a mild phenotype. 
In 2006, our research group [16] conducted the first population-based epidemiological study 
on congenital heart malformations in the São Miguel Island, where the results pointed out the 
great interest for genetic studies in order to understand the aetiology of these complex 
pathologies. Since 22q11.2 CNVs are frequently implicated in CHD, in the present work we 
assessed the presence or absence of these structural abnormalities in 87 patients, and explored 
the multiple clinical features of patients with CNVs. This study is the first molecular-based 
investigation of CHD in patients from the São Miguel Island. 
Results 
CHD patients with CNVs in the 22q11.2 region 
In the São Miguel Island, an epidemiological study carried out by our research group [16] 
demonstrated that the prevalence of CHD was relatively high, reaching 9.16/1000 live births. 
However, understanding the genetic features underlying CHD in patients from this island 
remains unknown. In order to investigate the presence of CNVs in the 22q11.2 region of 87 
CHD patients, we first performed a genetic screening using multiplex ligation-dependent 
probe amplification (MLPA) assay and, in the positive cases, we additionally tested by 
fluorescence in situ hybridization (FISH) and array comparative genomic hybridization 
(array-CGH). We detected CNVs in four patients (4.6%), one male (A) and three females (B, 
C, D). 
Patient A is a 17 year-old male who has a ventricular septal defect (VSD). During the first 
month of pregnancy, and before knowing her pregnancy, his mother took medication for 
hypertiroidism. At eight months of age, the patient had febrile seizures, which remained after 
heart surgery. During childhood, he was diagnosed with developmental delay, hyperactivity, 
epilepsy, scoliosis, feet bunions, and urogenital abnormality. Patient B is a 20 year-old 
female who presents restrictive interventricular communication, membranous sub-aortic 
stenosis, cognitive deficit and facial dysmorphism. The patient’s family is endogamous, since 
her grandparents are from the same village. Her mother had an advanced age at conception 
(42 year-old) and her father presents mild intellectual disability with learning difficulties. 
Patient C is a 24 year-old female who has an atrial septal defect (ASD), facial dysmorphism, 
mild developmental delay, and learning difficulties. This patient is from a consanguineous 
family, since two of her great-great-grandparents were siblings. All of her four siblings had 
CHD and three of them died. Patient D is an 11 year-old female who has a VSD detected 
immediately after birth. She also has facial dysmorphism, developmental delay, moderate 
psychomotor impairment, and hypocalcaemia. At 15 days of age, this patient underwent 
cardiac surgery. 
MLPA analysis 
The results showed that the 22q11.2 region was normal in 83 (95.4%) and abnormal in four 
patients (A to D; Table 1). In the patients with an abnormal region, we performed the analysis 
of the segments with structural variation. We detected a deletion of 14 probes, from the 
CLTCL1 to the LZTR1 genes (data not shown) in DNA samples of patients A and D. In order 
to determine if these deletions were inherited or acquired de novo, we further assessed the 
parents’ samples. This analysis revealed that the same region was normal in the parents of 
patients A and D, i.e., without any CNV. In patient B, we found that the same 14 probes were 
in higher doses than duplication, suggesting the presence of either a double disomy (2:2, two 
chromosomes with 22q11.2 duplication) or a tetrasomy (1:3, one normal chromosome and a 
22q11.2 triplication in the other). Among the patient’s parents, the 22q11.2 region was 
normal in her mother (1:1) and duplicated (1:2) in her father. Regarding patient C, the results 
evidenced a duplication of the 14 probes and of the TOP3B probe, while in her mother only 
the TOP3B was duplicated; her father was normal. 
Table 1 Summary of the screening of the 22q11.2 region in CHD patients and their 
parents 
Patient Person tested Age (yrs) 22q11.2 region Methods used 
A patient 17 deletion (de novo) MLPA, array-CGH 
 mother 47 normal MLPA 
 father 49 normal MLPA 
B patient 20 triplication (paternally inherited with extra copy) MLPA, FISH, array-CGH 
 mother 61 normal MLPA, FISH 
 father 63 duplication MLPA, FISH, array-CGH 
C patient 24 duplication (de novo) + TOP3B duplication MLPA, array-CGH 
 mother 55 normal + TOP3B duplication MLPA 
 father 58 normal MLPA 
D patient 11 deletion (de novo) MLPA, FISH, array-CGH 
 mother 38 normal MLPA 
 father 39 normal MLPA 
Analysis of CNVs by FISH and array-CGH 
We assessed the exact number of 22q11.2 copies among each chromosome by a molecular 
cytogenetic technique, namely FISH. The FISH results confirmed those obtained by MLPA 
in patients B and D. In patient B, FISH revealed a tetrasomy of 22q11.2 region, with one of 
the two chromosomes having a triplicated sign of probe N25 in metaphase (Figure 1A) and 
interphase (Figure 1B). The evaluation of this patient’s parents showed that the father carried 
a 22q11.2 duplication (Figures 1C and 1D), whose expansion could be the possible cause of 
the presence of triplication in his daughter (Figure 1B). A normal pattern was revealed in her 
mother’s homologous chromosomes (two signals, each on a 22q11.2 region), which did not 
present any structural rearrangement (Figure 1E). In patient D, the loss of one red signal was 
detected in metaphase (Figure 1F), confirming a deletion in the 22q11.2 region of one of her 
chromosomes. 
Figure 1 Photographs of FISH assays. FISH with specific red probe (N25) in patient B on 
the metaphase (A) and interphase (B) chromosomes. FISH image of the father of patient B on 
interphase (C) and metaphase (D). (E) Interphase and metaphase FISH image with red probe 
in the mother of patient B. (F) Metaphase FISH image revealed in patient D. 
We additionally performed array-CGH for the determination of the exact length of CNVs in 
the four patients, as well as in patient B’s father. This technique also allows the identification 
of the genes involved in the CNV region, using the UCSC Genome Browser. As observed in 
Figures 2A and 2B, the array-CGH assay detected the 22q11.21 deletion in patients A and D, 
respectively. The deletions include nucleotide positions 18,894,835 and 21,464,119 for 
patient A, and positions 18,894,835 and 21,505,417 for patient D, both with an extension of 
approximately 2.5 Mb. Although having different breakpoints, the deletion in both patients 
involved the same critical region of the 22q11.2 deletion syndrome (OMIM: #188400; 
#192430). This region includes 68 genes (UCSC Genome Browser), 39 included in the 
OMIM database, and 10 in the OMIM Morbid Map (OMIM: *606810-PRODH, *190315-
SLC25A1, *138720-GP1BB, *602054-TBX1, *116790-COMT, *605566-RTN4R, *613619-
SCARF2, *142360-HCF2, *604202-SNAP29, and *600574-LZTR1). Despite patient A 
presented some atypical clinical features for to the 22q11.2 deletion syndrome, such as the 
hyperactivity, epilepsy, and scoliosis, we did not detect other pathogenic CNVs within his 
genome. 
Figure 2 Graphics of array-CGH assays representing 2.5 Mb deletion within the 
22q11.2 region of patient A (A) and patient D (B). 
In patient B, we observed the 22q11.2 triplication (Figure 3A), which has an extension of 
approximately 3 Mb (nucleotide positions 18,661,724 to 21,917,251). Comparing with the 
genes mapped in 2.5 Mb 22q11.2 deletion, the triplicated region has more eight genes in the 
UCSC Genome Browser (i.e., 76), more four genes included in the OMIM database (i.e., 43), 
but the same 10 genes found in the OMIM Morbid Map. The patient B’s father presented a 
duplication with an extension of approximately 2.5 Mb (Figure 3B; nucleotide positions 
18,894,835 to 21,505,417), which is the critical region of the corresponding microduplication 
syndrome (OMIM: #608363). This duplicated region carries the same genes mapped in the 
22q11.2 deletion, namely: 68 in the UCSC Genome Browser, 39 in the OMIM database, and 
10 in the OMIM Morbid Map. 
Figure 3 Representative array-CGH profiles for (A) 22q11.2 triplication of 3 Mb in 
patient B, and for (B) 22q11.2 duplication of 2.5 Mb in patient B’s father. 
Regarding patient C, the array-CGH confirmed a 2.5 Mb duplication of the 22q11.2 region 
(Figure 4), which was also detected in patient B’s father (Figure 3B). Moreover, we found 
one duplication in the long arm of chromosome 22, in an extension of approximately 288 Kb 
(between nucleotide positions 22,261,450 to 22,549,717), which include two genes, PPMF1 
and TOP3B, being the last one previously described in the OMIM database (OMIM: 
*603582-TOP3B). The downstream extension of the critical region, i.e. TOP3B duplication, 
had been observed by MLPA assay. 
Figure 4 Analysis of 22q11.2 duplication of 2.5 Mb in patient C. 
Discussion 
Recent reports have shown that CNVs in the 22q11.2 region are detected in a significant 
proportion of patients with CHD [1,2]. In the present study, we identified new molecular 
features in CHD patients from the São Miguel Island, Azores. Indeed, out of the 87 patients 
born alive between 1983 and 2005, four displayed genomic rearrangements in the 
chromosome 22q11, namely deletions (two patients), duplication (one patient), and 
triplication (one patient). These results made possible the characterization of the aetiology in 
these four CHD patients, i.e., 4.6% of our cohort, as well as the association of CNVs with 
individual clinical features. 
The 22q11.2 deletion syndrome has been reported as the most common deletion syndrome 
[4,9]. With the use of MLPA, molecular cytogenetic and cytogenomic methods, we observed 
that two unrelated patients (A and D) had this syndrome, both carrying a 2.5 Mb deletion of 
the 22q11.2 region. The deletion was acquired de novo, since their parents showed a normal 
pattern by MLPA. This observation is in accordance with the literature, where most cases of 
this syndrome occur after de novo deletions [17,18]. Regarding the molecular mechanisms 
underlying the emergence of both 22q11.2 deletions reported here, we hypothesize to be 
inter-chromosomal (inter-chromatid) NAHR events in the regions containing LCR sequences, 
as suggested in the literature [4,5,19]. About 90% of 22q11.2 deletions usually involve a 3 
Mb region − the critical region of the 22q11.2 deletion syndrome −, from LCR22-A to 
LCR22-D [1,2,5]. The 22q11 deletions observed here (2.5 Mb) were included in this region, 
where the major disease genes are found. 
The array-CGH analysis determined that the 22q11.2 deletion included several genes, such as 
TBX1, COMT, and RTN4R. The TBX1 gene encodes a T-box transcription factor, and its 
haploinsufficiency is largely responsible for the physical malformations associated with 
22q11.2 deletion syndrome, such as CHD and dysmorphisms [10,20]. This deletion could 
explain the clinical features of patients A (such as developmental delay, scoliosis, feet 
bunions, and urogenital abnormality) and patient D (namely developmental delay and 
hypocalcaemia). Furthermore, the deletion also includes COMT and RTN4R genes, whose 
haploinsufficiency is related with mental and behavioural problems [9,19,21]. In fact, patient 
A presents epilepsy and hyperactivity, whereas patient D has moderate psychomotor 
impairment. According to the literature, the heart defects most frequently associated with 
chromosomal abnormalities are VSD, atrioventricular septal defect, and tetralogy of Fallot 
(TOF) [11]. Interestingly, our results corroborate this observation, since patients A and D, 
who are affected with the 22q11.2 deletion syndrome, presented a VSD. 
The third patient (patient B) carried a 22q11.2 tetrasomy, with one copy in one chromosome 
and three copies in the other (1:3). This triplication could be explained by NAHR or by 
unequal crossing-over mechanism during gametogenesis, mediated by the presence of LCRs 
in the 22q11.2 region [22]. Nevertheless, other hypotheses for the emergence of a triplication 
are also possible, namely the replication-based mechanisms that underlie complex 
rearrangements, such as break-induced replication, fork stalling and template switching 
and/or microhomology-mediated break-induced replication [23,24]. The evaluation of patient 
B’s parents revealed a 2.5 Mb duplication in her father, suggesting a paternal inheritance with 
an extra copy. This mode of inheritance may be supported by results from a short tandem 
repeats/single nucleotide polymorphisms (STRs/SNPs) approach, the only strategy that 
determines the parental origin of de novo CNVs. Despite the different sizes between the 
CNVs of patient B (3 Mb) and her father (2.5 Mb), we observed an overlapping of the same 
10 disease-causing genes, presently registered in the OMIM Morbid Map, but in different 
gene dosages: patient B has the expression of four gene copies (1:3), whereas her father has 
three (1:2). To the best of our knowledge, patient B is the second documented case of a 
22q11.2 triplication, since the first one was previously described by Yobb and collaborators 
[14]. These authors reported that the 22q11.2 triplication caused mild phenotypes, including 
dysmorphic features, hearing impairment, cognitive deficit, behavioural problems, and left 
ear pit. In the present study, the patient displayed the typical dysmorphic facial features seen 
in patients with the 22q11.2 deletion and microduplication syndromes, cognitive deficit, and 
heart defects (a restrictive interventricular communication and a membranous sub-aortic 
stenosis). Interestingly, these clinical features are similar to those of 22q11.2 deletion 
syndrome patients but, because include heart defects, they are not considered mild. Taking 
this into consideration, we propose that 22q11.2 triplication is a variation of 22q11.2 
microduplication syndrome, with an aggravated phenotype due to the major dosage of 
implicated genes. 
The last patient (patient C) presented the 22q11.2 microduplication syndrome, carrying a de 
novo 2.5 Mb duplication of this critical region, which could probably be generated during 
gametogenesis by NAHR [4,19,25] or by unequal crossing-over [8]. To determine the 
parental origin of this CNV, the same STRs/SNPs strategy suggested for patient B would be 
useful. This syndrome has also been characterized as a different clinical entity with features 
overlapping 22q11.2 deletion syndrome [6]. Duplications are associated with high phenotypic 
variability, including intellectual disability, cognitive deficit, hypotonia, developmental 
delay, and cardiac heart defects (including VSD, TOF, hypoplastic left heart syndrome, and 
interrupted aortic arch), as well as normal or near normal phenotype [6,8]. Although carrying 
the same duplication, patient C and the father of patient B presented different phenotypes. 
Patient C exhibited ASD, mild developmental delay, and learning difficulties, whereas patient 
B’s father only has mild intellectual disability with learning difficulties (without CHD). 
These highly variable cardiac phenotypes and discrepancies could be explained by altered 
TBX1 expression together with other additional genetic, epigenetic, and/or non-genetic 
factors required for full expressivity [8]. Thus, the great variability of the 22q11.2 
microduplication syndrome’s severity is the major difficulty in the establishment of 
genotype-phenotype correlation in the 22q11.2 region. Moreover, in patient C, the short 
duplication of 288 Kb, which included the TOP3B gene, was inherited from her healthy 
mother and has been described as benign because it was detected in control individuals [26]. 
However, we cannot exclude the possibility of a combination of the 2.5 Mb 22q11.2 region 
and TOP3B gene duplications for the manifestation of such kind of phenotypes in patient C. 
According to Sørensen and collaborators [2], the MLPA technique could be used within 
paediatric cardiology as a first tier screen to detect clinically relevant CNVs and to identify 
syndromic patients at an early stage. In the present study, all patients were examined with 
more than one method and, in each case, the results concurred. The advantage of the MLPA 
assay compared to FISH and array-CGH is that it is relatively simple to use in clinical 
laboratories of small or medium-scale dimension, and the reagent cost per assay is cheaper 
than the other two methods [2,5,27,28]. However, MLPA Kit P250 is not thorough enough 
for the accurate determination of the sizes of 22q11.2 CNVs and only allows the detection of 
unbalanced chromosomal rearrangements. As a consequence, the complementary use of 
array-CGH is advised, since this method is able to perform the fine mapping of the 22q11.2 
region. FISH could be required for the screening of balanced rearrangements, essentially in 
terms of accurate familial genetic counselling [29], and for in situ validation of results. 
Moreover, the aetiology of CHD patients without CNVs needs other molecular analyses, such 
as the large-scale mutation screening by exome and cDNA sequencing or a strategy based on 
the analysis of SNPs in candidate genes. We are planning to use some of these techniques to 
further study the remaining 83 CHD patients without 22q11.2 CNVs. 
Conclusions 
In summary, this report is the first study investigating the molecular basis of CHD among 
patients from the São Miguel Island. Based on a molecular approach combining MLPA, 
FISH, and array-CGH techniques, we identified CNVs in the 22q11.2 region of four patients, 
4.6% of our cohort: two de novo deletions (patients A and D), one de novo duplication 
(patient C), and one triplication paternally inherited with an extra copy (patient B). To the 
best of our knowledge, the latter patient is the second documented case of a 22q11.2 
triplication. The data presented here also suggest that triplications of chromosome 22q11.2, 
although they share some characteristic features with deletion and microduplication 
syndromes, represent a more severe variant, which are genomically distinct from these well-
known syndromes. Finally, the detected CNVs emphasize the relevance of biomedical 
research, since it can help paediatricians and other professionals to better assess health care 
needs. 
Methods 
Ethical statement 
This work was approved by the Health Ethics Committee from the Hospital of Divino 
Espírito Santo of Ponta Delgada, EPE (HDES). Written informed consent for patients’ 
inclusion in the study was obtained from their parents or from the patient himself/herself 
when he/she had at least 18 year-old. All the parents included in this work also authorized 
their own participation. Additionally, individuals with CNVs and their parents also gave 
informed consent to publish their medical and/or genetic information. 
CHD patient screening strategy 
The present study was based on the Azorean Registry of CHD, established in 1992, at the 
HDES, the main hospital in the Azores Islands. The study population consisted of 87 children 
with heart disease, born alive between 1983 and 2005 in São Miguel Island. Most of the 
patients were previously included in an epidemiological study of our research group [16]. 
MLPA 
Genomic DNA from all patients and parents was extracted from peripheral blood 
lymphocytes using Puregene Blood Kit (Gentra Systems, Minneapolis, USA) or Citogene 
Blood Kit (Citomed, Lisbon, Portugal), following the manufacturer’s instructions. DNA 
concentration and purity were evaluated using Beckman DU 530 (Beckman Coulter, Brea, 
USA) or NanoDrop1000 spectrophotometer (Thermo Scientific, Waltham, USA). The study 
of the 22q11.2 region was performed by MLPA, using the P250-B1 Kit (MRC-Holland, 
Amsterdam, The Netherlands) and according to the standard protocol supplied by the 
manufacturer [30]. A mix of 1 μl PCR product, 9.2 μl Hi-Di formamide and 0.2 μl GeneScan 
500 LIZ Size Standard was analyzed by capillary electrophoresis in an ABI 3130 Genetic 
Analyzer (Applied Biosystems, Foster City, USA). MLPA data were collected using 
GeneMapper software (Applied Biosystems, Foster City, USA), and subsequently analyzed 
against up to four control samples with the MRC Coffalyser v7 software. 
FISH 
FISH analysis of chromosome 22q11.2 was performed in metaphases and/or interphases, 
obtained from the synchronous culture of lymphocytes, using the commercially available 
probe N25 (locus D22S75; Cytocell, Cambridge, UK). Slide preparation, denaturation, and 
hybridization were carried out according to the manufacturer’s protocols. 
Array-CGH 
Genomic DNA extraction from peripheral blood lymphocytes was carried out with the 
Jetquick Blood and Cell Culture DNA Midi Spin Kit (Genomed, Löhne, Germany), 
according to the manufacturer’s instructions. DNA concentration and purity were evaluated 
using a NanoDrop1000 spectrophotometer. Array-CGH was performed for fine mapping of 
the 22q11.2 region, using the Agilent SurePrint G3 Human Genome Microarray 4X180K 
(Agilent Technologies, Santa Clara, USA). Labeling and hybridization were carried out with 
sex-matched reference DNA by using an Agilent Genomic DNA Enzymatic Labeling Kit 
(Agilent Technologies, Santa Clara, USA), according to the manufacturer’s instructions. 
Array slides images were acquired on an Agilent scanner and the data were processed with 
Feature Extraction software (v10.7). Results were analyzed with Agilent Genomic 
Workbench (v6.5) and Agilent Cytogenomics (v2.7.7.0), according to Human Genome build 
19, and interpreted by databases consultation. Regions of copy number change were 
interpreted with the aid of the UCSC Genome Browser [31]. 
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